Biblio

Author Title Type [ Year(Asc)]
Filters: Author is van der Velden, Jolanda  [Clear All Filters]
2024
Wijnker PJM, Dinani R, van der Laan NC, Algül S, Knollmann BC, Verkerk AO, Remme CAnn, Zuurbier CJ, Kuster DWD, van der Velden J. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by SGLT2 inhibitors. Cardiovasc Res. 2024.
Schwach V, Slaats RH, Cofiño-Fabres C, Den SATen, Rivera-Arbeláez JM, Dannenberg M, van Boheemen C, Ribeiro MC, van der Zanden SY, Nollet EE, et al. A safety screening platform for individualized cardiotoxicity assessment. iScience. 2024;27(3):109139.
2023
Dinani R, Manders E, Helmes M, Wang L, Knollmann B, Kuster DWD, van der Velden J. Real-Time Measurements of Calcium and Contractility Parameters in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. J Vis Exp. 2023;(195).
2022
Sequeira V, Wang L, Wijnker PJM, Kim K, Pinto JR, Remedios CDos, Redwood C, Knollmann BC, van der Velden J. Low expression of the K280N mutation is sufficient to increase basal myofilament activation in human hypertrophy cardiomyopathy. J Mol Cell Cardiol Plus. 2022;1:100007.
2021
de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, Eschenhagen T, Filippatos G, Gepstein L, Hulot J-S, et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets. Eur J Heart Fail. 2021.
Flenner F, Jungen C, Küpker N, Ibel A, Kruse M, Koivumäki JT, Rinas A, Zech ATL, Rhoden A, Wijnker PJM, et al. Translational investigation of electrophysiology in hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2021.
2020
Buikema JW, Lee S, Goodyer WR, Maas RG, Chirikian O, Li G, Miao Y, Paige SL, Lee D, Wu H, et al. Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Cell Stem Cell. 2020;27(1):50-63.e5.